[go: up one dir, main page]

WO2018191802A1 - Dispositif pour l'application de biopolymères de fibrine - Google Patents

Dispositif pour l'application de biopolymères de fibrine Download PDF

Info

Publication number
WO2018191802A1
WO2018191802A1 PCT/BR2018/050103 BR2018050103W WO2018191802A1 WO 2018191802 A1 WO2018191802 A1 WO 2018191802A1 BR 2018050103 W BR2018050103 W BR 2018050103W WO 2018191802 A1 WO2018191802 A1 WO 2018191802A1
Authority
WO
WIPO (PCT)
Prior art keywords
components
independent
biopolymer
chambers
biopolymers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2018/050103
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Silvia SARTORI BARRAVIERA SEABRA FERREIRA
Moacyr RAMOS BIGHETTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaivo Pesquisa E Desenvolvimento Em Saude Ltda
Original Assignee
Kaivo Pesquisa E Desenvolvimento Em Saude Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaivo Pesquisa E Desenvolvimento Em Saude Ltda filed Critical Kaivo Pesquisa E Desenvolvimento Em Saude Ltda
Publication of WO2018191802A1 publication Critical patent/WO2018191802A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/0005—Components or details
    • B05B11/0078—Arrangements for separately storing several components
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/68—Dispensing two or more contents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B12/00—Arrangements for controlling delivery; Arrangements for controlling the spray area
    • B05B12/14—Arrangements for controlling delivery; Arrangements for controlling the spray area for supplying a selected one of a plurality of liquids or other fluent materials or several in selected proportions to a spray apparatus, e.g. to a single spray outlet
    • B05B12/1472—Arrangements for controlling delivery; Arrangements for controlling the spray area for supplying a selected one of a plurality of liquids or other fluent materials or several in selected proportions to a spray apparatus, e.g. to a single spray outlet separate supply lines supplying different materials to separate outlets of the spraying apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant
    • B65D83/141—Containers for dispensing liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant specially adapted for specific contents or propellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00491—Surgical glue applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00491—Surgical glue applicators
    • A61B2017/00495—Surgical glue applicators for two-component glue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0445—Proteins
    • A61M2202/0447—Glycoproteins
    • A61M2202/045—Fibrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B7/00—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
    • B05B7/02—Spray pistols; Apparatus for discharge
    • B05B7/08—Spray pistols; Apparatus for discharge with separate outlet orifices, e.g. to form parallel jets, i.e. the axis of the jets being parallel, to form intersecting jets, i.e. the axis of the jets converging but not necessarily intersecting at a point
    • B05B7/0876—Spray pistols; Apparatus for discharge with separate outlet orifices, e.g. to form parallel jets, i.e. the axis of the jets being parallel, to form intersecting jets, i.e. the axis of the jets converging but not necessarily intersecting at a point to form parallel jets constituted by a liquid or a mixture containing a liquid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B7/00—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
    • B05B7/02—Spray pistols; Apparatus for discharge
    • B05B7/08—Spray pistols; Apparatus for discharge with separate outlet orifices, e.g. to form parallel jets, i.e. the axis of the jets being parallel, to form intersecting jets, i.e. the axis of the jets converging but not necessarily intersecting at a point
    • B05B7/0892—Spray pistols; Apparatus for discharge with separate outlet orifices, e.g. to form parallel jets, i.e. the axis of the jets being parallel, to form intersecting jets, i.e. the axis of the jets converging but not necessarily intersecting at a point the outlet orifices for jets constituted by a liquid or a mixture containing a liquid being disposed on a circle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B7/00—Spraying apparatus for discharge of liquids or other fluent materials from two or more sources, e.g. of liquid and air, of powder and gas
    • B05B7/02—Spray pistols; Apparatus for discharge
    • B05B7/10—Spray pistols; Apparatus for discharge producing a swirling discharge

Definitions

  • the present invention relates to a novel device for applying fibrin biopolymers, and more specifically for applying fibrin biopolymers consisting of two or more components that need to be mixed only at the time of use. More particularly, but not restrictively, the invented applicator device is intended for the application of fibrin biopolymers obtained exclusively from materials of animal origin, notably:. snake venom-purified thrombin-like, or the use of the same component from its synthesis in the laboratory by methods known to science (produced by recombinant technology to extract its active, synthetic form from prokaryotic organisms, eg bacteria, or eukaryotes, eg fungi and yeast, or other methods for the same purpose); and //.
  • materials of animal origin notably:. snake venom-purified thrombin-like, or the use of the same component from its synthesis in the laboratory by methods known to science (produced by recombinant technology to extract its active, synthetic form from prokaryotic organisms, eg bacteria, or eukary
  • Said applicator device can be purchased commercially in pharmacies without the need for a prescription, and allows the user to apply the fibrin biopolymer topically without the assistance of a specialized medical professional.
  • some medicines are made up of two or more biological components which necessarily have to be mixed only at the time of application to achieve certain properties.
  • An example of such a medicine is fibrin biopolymers obtained from human blood, long known in the art. Said biopolymers are used in surgical procedures, with the purpose of reducing the bleeding and provide a firm grip between the tissues.
  • fibrin is a natural biopolymer which, due to its bioactivity, biocompatibility and biodegradability characteristics, has been widely used in wound healing. Because they provide excellent tissue sealing and bonding properties, such fibrin biopolymers have commonly been called fibrin "sealants” or "glues”.
  • fibrin biopolymers Since the 1970s, several new proposals for fibrin biopolymers have been developed, also involving the mixing of these two components (fibrinogen and thrombin), but only one of them continues to be extracted from humans (fibrinogen). , while human thrombin was replaced by bovine thrombin or snake venom purified thrombin.
  • fibrin biopolymer is that described in BR PI 9103724-7, published 30/03/1993, concerning a "COBRA POIS DERIVATED FIBRIN ADHESIVE FOR PREPARATION".
  • the fibrin glue consisted of two solutions, one consisting of a fibrinogen-rich cryoprecipitate obtained from fresh human plasma, and the other consisting of a fraction of lyophilized snake venom.
  • fibrin biopolymers already known in the art are those described in WO 2007/121748, published 11/01/2007, and US 9,446,166, published 7/24/2014.
  • fibrin biopolymer (cryoprecipitate containing fibrinogen) invariably comes from humans.
  • both components human fibrinogen and thrombin
  • both components need to be kept frozen at negative 20 ° C to avoid losing their properties, and at the time of biopolymer use they need to be kept frozen. be thawed and mixed.
  • applicator devices are also known in the art, formed either by two communicable chambers, or by two contiguous syringes, each comprising one of the biopolymer components, as well as by a mixing chamber capable of mix them when applying the biopolymer to the surface of the tissue or organ to be treated;
  • Such devices also need to be stored in freezers to keep frozen components inside.
  • these devices can only be handled by medical professionals (doctors or nurses) who are already used to operating surgical instruments.
  • fluidization is the process by which solid particles are transformed into liquid state by suspending them in a gas or liquid.
  • a carrier gas preferably carbon dioxide or nitrogen dioxide
  • the fine particles of a drug and / or biopolymer are fluidized by a carrier gas. (preferably carbon dioxide or nitrogen dioxide) or any liquid solution.
  • a carrier gas preferably carbon dioxide or nitrogen dioxide
  • such components are injected into a microtube, where the powder and liquid or gas come into contact and are mixed. The resulting mixture is then sprayed from the tip of the microtube to the body site to be treated.
  • Said fibrin biopolymers known in the art being obtained from human blood, present a number of problems.
  • One of them lies in the fact that human blood used in biopolymer production can contain contaminating factors, such as contagious viruses, among others, and can therefore be a potentially transmitting element of infectious diseases.
  • fibrin biopolymers are an expensive and scarce product that is handcrafted within laboratories on a very small scale, and which can be used only and only in hospital settings by skilled professionals in the field. doctor. Currently, this production only occurs in laboratories abroad, there is no production by the Brazilian national industry.
  • fibrin biopolymers to date have never been able to constitute a commercially available, commercially available end-consumer product that can be purchased as an over-the-counter (OTC) drug.
  • OTC over-the-counter
  • fibrin biopolymers being an extremely expensive and scarce product, are only available between the walls of hospital and university laboratories (and produced only abroad), where they are kept frozen, and only employed when urgently needed in major surgeries, in the hospital setting itself, where they are thawed shortly before their application by doctors or nurses themselves during surgery.
  • the fibrin sealant provided therein is comprised of a serinoprotease purified from snake venom, a fibrinogen-rich cryoprecipitate extracted from large animals, preferably buffalo (buffalo), and by a diluent configured by calcium chloride.
  • a serinoprotease purified from snake venom a fibrinogen-rich cryoprecipitate extracted from large animals, preferably buffalo (buffalo)
  • a diluent configured by calcium chloride.
  • the diluent is first injected into the vial containing serinoprotease and shaken and set aside. Using a syringe and needle, the whole contents of this vial (diluted serinoprotease) are aspirated. With another syringe and needle, aspirate the entire contents of the vial containing cryoprecipitate. Then, the topical application of the two components, with both syringes in parallel and their respective bevels directed to the site to be treated, said components polymerizing "in situ", after being properly mixed.
  • the predicted fibrin sealant described in BR 10 2014 011436-0 has a highly coagulant effect, capable of clogging blood vessels, and thus stopping bleeding immediately, and yet creates a transparent film over the application site, which accelerates cell multiplication, speeding tissue healing and recovery by stimulating the emergence of new blood vessels.
  • the fibrin sealant described in BR 10 2014 011436-0 still requires that its components (serinoprotease purified from snake venom and fibrinogen-rich cryoprecipitate extracted from large animals) are kept frozen until the time of use, thus continuing to limit the manufacture and use of hospital environments.
  • Such a device should have such features as to enable end-user acquisition of the biopolymer at the point of sale, without the need for medical prescription, and to enable the user to apply this biopolymer in a simple and easy manner without the assistance of any medical professional (doctor or nurse).
  • the Depositor has created this new "FIBRINE BIOPOLYMER APPLICATION DEVICE", which is configured by a spray bottle, internally provided with independent chambers, which house the various components of the biopolymer. From said chambers, respective independent ducts depart, which, within the spray nozzle of the vial, are interconnected with respective, equally independent, helical channels, duly coiled together, terminating in respective equally independent spray nozzles.
  • said flask is provided with three independent and watertight chambers, designed to house respectively two powder components and a diluent liquid.
  • the two powdered components may be serinoprotease purified from snake venom and fibrinogen-rich cryoprecipitate extracted from large animals.
  • the applicator device is more specifically intended for the application of fibrin biopolymers consisting of components of animal origin only, notably:.
  • serinoprotease purified from snake venom or the use of the same component from its synthesis in the laboratory by methods known to science (produced by recombinant technology for the purpose of extracting its synthetic form, active, being from prokaryotic organisms, eg bacteria, or eukaryotes, eg fungi and yeast, or other methods with the same purpose); and //. the fibrinogen-rich cryoprecipitate extracted from large animals, said device thus lending more particularly, but not restrictively, to the application of the fibrin sealant described in BR 10 2014 011436-0.
  • the two powder components and the diluent liquid contained in the three independent chambers of the vial are helically sprayed into the ambient air independently and concomitantly. from the respective three independent spray nozzles at a predetermined distance from the surface of the wound to be treated, the three components being then properly mixed in the air during the course of that distance to achieve the already properly homogenized and polymerized wound in the form of a transparent sealant film.
  • serinoprotease purified from snake venom or the use of the same component from its synthesis in the laboratory by methods known to science (produced by recombinant technology to extract its active synthetic form from from prokaryotic organisms, eg bacteria, or eukaryotes, eg fungi and yeast, or other methods for the same purpose); and //. the fibrinogen-rich cryoprecipitate extracted from large animals.
  • the new applicator device will allow, for the first time, the supply of fibrin biopolymers in the form of an end product itself, which can be manufactured on an industrial scale at low cost without requiring the freezing of its components, which product will be commercially available at points of sale (pharmacies and drugstores), and that can be purchased and used by the consumer, outside the hospital environment, without the need for medical prescription, and without the presence of a specialized professional. from the medical field.
  • This product can be applied to general injuries, from small cuts resulting from simple household accidents (knife cuts, razor blades, scratches, tearing injuries, etc.) to large wounds, constituting a highly complex product. effective for stopping bleeding and accelerating tissue healing by stimulating the emergence of new blood vessels.
  • Figure 1 is a schematic view of the fibrin biopolymer applicator device now innovated
  • Figures 2 and 3 illustrate said device respectively by longitudinal and transverse sections
  • FIGS. 4 and 5 are enlarged and equally schematic details of said applicator device.
  • the present invention relates to a "FIBRINE BIOPOLYMER APPLICATION DEVICE", device (1) which is configured by a spray bottle (2) internally provided with two or more independent and watertight chambers ( 2a), which house, respectively, the various components of the sealant. From said chambers (2a), respective independent ducts (3) depart which, within the spray nozzle (4) of the vial (1), interconnect with respective independent channels (5) initially developed in inclined sections (5a). ), and then in coiled sections (5b) duly wound together, terminating in respective equally independent spray nozzles (6).
  • said vial (2) is provided with three independent, watertight chambers (2a) for respectively housing two powdered components (serinoprotease purified from snake venom and fibrinogen-rich cryoprecipitate extracted from large animals). ) and a diluent liquid, which are the components of the fibrin sealant provided for in BR 10 2014 011436-0.
  • Spraying of the components is achieved by pumping under high pressure a propellant gas (preferably inert carbon dioxide). ) provided inside the vial (2), responsible for the exposure of the three said components of their respective chambers (2a), which, passing through the respective independent ducts (3), reach the interior of the respective also independent helical channels (5) spray nozzle (4), reaching the outside through the equally independent spray nozzles (6).
  • a propellant gas preferably inert carbon dioxide
  • the effective mixture between components occurs outside the device, that is, in the external ambient air, only after spraying them.
  • the spray nozzles (6) of the spray nozzle (4) as they reach the outside of the bottle with continue to disperse in ambient air in helical motions, initially caused by the inner helical channels (5), mixing with each other along the path between the spray nozzles (6) of the spray nozzle (4) and the surface of the wound to be treated, and forming on said surface, the aforementioned transparent sealing film.
  • the biopolymer components are mixed and applied at the moment of use, in a simple, practical and immediate way, eliminating the need for freezing of the components.
  • the new applicator device more particularly is obtained the mixing and application of the components of fibrin biopolymers in general, and even more particularly of fibrin biopolymers consisting exclusively of components of animal origin, with which it was possible for the first time to provide such biopolymers in the form of a final product itself, manufactured on an industrial scale, at a low cost, commercially available at points of sale (pharmacies and drugstores), and obtainable and used by the consumer himself, without the need for medical prescription, outside the hospital environment and without the presence of a specialized medical professional.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Surgical Instruments (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Nozzles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un dispositif pour l'application de biopolymères de fibrine, comprenant deux ou plusieurs constituants qui ne doivent être mélangés qu'au moment de l'utilisation, ledit dispositif (1) étant constitué par un flacon de pulvérisation (2) intérieurement pourvu de chambres indépendantes et étanches (2a) qui reçoivent les constituants du biopolymère, et à dont partent des conduits indépendants (3) qui sont reliés à des canaux respectives également indépendants (5), conçus sous forme de segments inclinés (5a) et hélicoïdaux (5b) enroulés entre eux, et se terminant en embouts pulvérisateurs (6). Les constituants contenus dans les chambres (2a) sont pulvérisés et mélangés, leur mélange se produisant à l'extérieur du dispositif, après leur pulvérisation par les embouts pulvérisateurs (6), lorsqu'ils atteignent l'extérieur du flacon. Lesdits constituants, par inertie, continuent à se disperser dans l'air ambiant en mouvements hélicoïdaux, et se mélangent tout au long du parcours entre les embouts asperseurs (6) et la plaie.
PCT/BR2018/050103 2017-04-18 2018-04-16 Dispositif pour l'application de biopolymères de fibrine Ceased WO2018191802A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR102017008028-5 2017-04-18
BR102017008028-5A BR102017008028B1 (pt) 2017-04-18 2017-04-18 Dispositivo para aplicação de biopolímeros de fibrina

Publications (1)

Publication Number Publication Date
WO2018191802A1 true WO2018191802A1 (fr) 2018-10-25

Family

ID=63855525

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2018/050103 Ceased WO2018191802A1 (fr) 2017-04-18 2018-04-16 Dispositif pour l'application de biopolymères de fibrine

Country Status (2)

Country Link
BR (1) BR102017008028B1 (fr)
WO (1) WO2018191802A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212106A1 (fr) * 2022-01-13 2023-07-19 Cuantum Medical Cosmetics, S.L. Dispositif portable permettant d'appliquer une composition adhésive de cyanoacrylate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100217231A1 (en) * 2009-02-20 2010-08-26 Erez Ilan Device for administering an at least two-component substance
US20120076930A1 (en) * 2008-10-14 2012-03-29 Harris Richard Miller Chemiluminescent Aerosol Spray
WO2014071395A2 (fr) * 2012-11-05 2014-05-08 Smith & Nephew, Inc. Ensembles et procédés d'administration de fluide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076930A1 (en) * 2008-10-14 2012-03-29 Harris Richard Miller Chemiluminescent Aerosol Spray
US20100217231A1 (en) * 2009-02-20 2010-08-26 Erez Ilan Device for administering an at least two-component substance
WO2014071395A2 (fr) * 2012-11-05 2014-05-08 Smith & Nephew, Inc. Ensembles et procédés d'administration de fluide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212106A1 (fr) * 2022-01-13 2023-07-19 Cuantum Medical Cosmetics, S.L. Dispositif portable permettant d'appliquer une composition adhésive de cyanoacrylate

Also Published As

Publication number Publication date
BR102017008028A2 (pt) 2018-10-30
BR102017008028B1 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
Du et al. Hemostasis strategies and recent advances in nanomaterials for hemostasis
Sabatini et al. Fibrin tissue adhesive reduces postoperative blood loss in total knee arthroplasty
JP5160101B2 (ja) 血管、医療システム、および医療器具、をふさぐための方法
Holcomb et al. Fibrin sealant foam sprayed directly on liver injuries decreases blood loss in resuscitated rats
Mintz et al. Fibrin sealant: clinical use and the development of the University of Virginia Tissue Adhesive Center
BR112021022136A2 (pt) Composições de tecido formados de maneira atraumática, dispositivos e métodos de preparação e tratamento
Foster et al. A chitosan based, laser activated thin film surgical adhesive,'SurgiLux': preparation and demonstration
Kheirabadi et al. Clot-inducing minerals versus plasma protein dressing for topical treatment of external bleeding in the presence of coagulopathy
JP2010284512A (ja) フィブリン接着剤塗布用装置
CN105816905A (zh) 一种具有促愈合功能的可吸收骨蜡及其制备方法
Xiao et al. A narrative review of different hemostatic materials in emergency treatment of trauma
Kim et al. Effect of fibrin sealant in positioning and stabilizing microvascular pedicle: A comparative study
Ortenzi et al. Safety and feasibility of PuraStat® in laparoscopic colorectal surgery (feasibility study)
Tanghe et al. Hemostatic agents in orthopedic surgery
WO2018191802A1 (fr) Dispositif pour l'application de biopolymères de fibrine
Ogle et al. Hemostatic agents
Wang et al. Experience improves successful use of fibrin sealant in total knee arthroplasty: implications for surgical education
WO2018191800A1 (fr) Dispositif pour l'application de biopolymères de fibrine
Oliver et al. Local pro-and anti-coagulation therapy in the plastic surgical patient: A literature review of the evidence and clinical applications
de Carvalho et al. Mechanism of action of topical hemostatic and adhesive tissue agents
BR102017008027B1 (pt) Processo de obtenção de biopolímero de fibrina, meios de aplicação do referido biopolímero de fibrina, e processo de aplicação do referido biopolímero de fibrina
Schremmer New concepts in wound management
Szukics et al. Optimizing Outcomes in Shoulder Arthroplasty: Mitigating Surgical Complications in High-Risk Patients–Case Report
HUANG Progress in diagnosis and treatment of posterior condylar fracture of tibial plateau
RU2628809C1 (ru) Гемостатическая губка и способ ее получения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18787264

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18787264

Country of ref document: EP

Kind code of ref document: A1